QHP Capital’s $1.1 Billion Azurity Continuation Fund Shows Scale in Healthcare Secondaries

A Billion-Dollar GP-Led Deal in Healthcare QHP Capital's completion of a $1.1 billion continuation fund for Azurity Pharmaceuticals is a reminder that GP-led secondaries are now operating at substantial scale. Healthcare remains one of the sectors best suited to these transactions because buyers can underwrite durable demand, defensible market positioning, and longer value-creation runways. In a more cautious exit market, large continuation funds have become an efficient way to keep premium assets in experienced hands while still delivering liquidity to legacy investors. Why Healthcare Continues to Attract Secondary Capital Revenue visibility and resilience can support large single-asset underwrites. Sector specialization helps both sponsors and buyers assess execution risk more precisely. Healthcare businesses often have strategic optionality that may not be fully realized on a forced sale timeline. The Azurity deal suggests that sophisticated buyers remain willing to write large checks for mature, high-quality assets when structure and underwriting align. Read-Through for the GP-Led Market Large transactions such as this one matter because they deepen confidence in GP-led processes as a credible alternative to M&A exits or IPOs. They also show that the market can absorb sizable deals when sponsors present assets with strong track records and a compelling next chapter. That is important for managers sitting on quality companies but still facing a selective realization environment. Why This Matters for Private Markets The Azurity continuation fund demonstrates that scale is no longer a constraint for well-structured GP-led deals. For private markets, that supports higher confidence in continuation vehicles as a repeatable solution for premium assets, particularly in sectors where diligence depth and operating visibility can justify large commitments.